Literature DB >> 23518664

Neurodegenerative disease phenotypes in carriers of MAPT p.A152T, a risk factor for frontotemporal dementia spectrum disorders and Alzheimer disease.

Suzee E Lee1, Maria C Tartaglia, Görsev Yener, Sermin Genç, William W Seeley, Pascual Sanchez-Juan, Fermin Moreno, Mario F Mendez, Eric Klein, Rosa Rademakers, Adolfo López de Munain, Onofre Combarros, Joel H Kramer, Robert O Kenet, Adam L Boxer, Michael D Geschwind, Maria-Luisa Gorno-Tempini, Anna M Karydas, Gil D Rabinovici, Giovanni Coppola, Daniel H Geschwind, Bruce L Miller.   

Abstract

Recently, Coppola and colleagues demonstrated that a rare microtubule-associated protein tau (MAPT) sequence variant, c.454G>A (p.A152T) significantly increases the risk of frontotemporal dementia (FTD) spectrum disorders and Alzheimer disease (AD) in a screen of 15,369 subjects. We describe clinical features of 9 patients with neurodegenerative disease (4 women) harboring p.A152T, aged 51 to 79 years at symptom onset. Seven developed FTD spectrum clinical syndromes, including progressive supranuclear palsy syndrome (n=2), behavioral variant FTD (bvFTD, n=1), nonfluent variant primary progressive aphasia (nfvPPA, n=2), and corticobasal syndrome (n=2); 2 patients were diagnosed with clinical AD. Thus, MAPT p.A152T is associated with a variety of FTD spectrum clinical presentations, although patients with clinical AD are also identified. These data warrant larger studies with clinicopathologic correlation to elucidate the influence of this genetic variant on neurodegenerative disease.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23518664      PMCID: PMC3796183          DOI: 10.1097/WAD.0b013e31828cc357

Source DB:  PubMed          Journal:  Alzheimer Dis Assoc Disord        ISSN: 0893-0341            Impact factor:   2.703


  30 in total

1.  Procerus sign in progressive supranuclear palsy.

Authors:  S Romano; C Colosimo
Journal:  Neurology       Date:  2001-11-27       Impact factor: 9.910

2.  The Clinical Dementia Rating (CDR): current version and scoring rules.

Authors:  J C Morris
Journal:  Neurology       Date:  1993-11       Impact factor: 9.910

3.  Late-onset frontotemporal dementia with a novel exon 1 (Arg5His) tau gene mutation.

Authors:  Shintaro Hayashi; Yasuko Toyoshima; Masato Hasegawa; Yuri Umeda; Koichi Wakabayashi; Susumu Tokiguchi; Takeshi Iwatsubo; Hitoshi Takahashi
Journal:  Ann Neurol       Date:  2002-04       Impact factor: 10.422

4.  Pathologic heterogeneity in clinically diagnosed corticobasal degeneration.

Authors:  B F Boeve; D M Maraganore; J E Parisi; J E Ahlskog; N Graff-Radford; R J Caselli; D W Dickson; E Kokmen; R C Petersen
Journal:  Neurology       Date:  1999-09-11       Impact factor: 9.910

5.  Distinctive neuropsychological patterns in frontotemporal dementia, semantic dementia, and Alzheimer disease.

Authors:  Joel H Kramer; Jennifer Jurik; Sharon J Sha; Kate P Rankin; Howard J Rosen; Julene K Johnson; Bruce L Miller
Journal:  Cogn Behav Neurol       Date:  2003-12       Impact factor: 1.600

6.  Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease.

Authors:  G McKhann; D Drachman; M Folstein; R Katzman; D Price; E M Stadlan
Journal:  Neurology       Date:  1984-07       Impact factor: 9.910

7.  Diagnostic accuracy of progressive supranuclear palsy in the Society for Progressive Supranuclear Palsy brain bank.

Authors:  Keith A Josephs; Dennis W Dickson
Journal:  Mov Disord       Date:  2003-09       Impact factor: 10.338

8.  An R5L tau mutation in a subject with a progressive supranuclear palsy phenotype.

Authors:  Parvoneh Poorkaj; Nancy A Muma; Victoria Zhukareva; Elizabeth J Cochran; Kathleen M Shannon; Howard Hurtig; William C Koller; Thomas D Bird; John Q Trojanowski; Virginia M-Y Lee; Gerard D Schellenberg
Journal:  Ann Neurol       Date:  2002-10       Impact factor: 10.422

9.  Cognition and anatomy in three variants of primary progressive aphasia.

Authors:  Maria Luisa Gorno-Tempini; Nina F Dronkers; Katherine P Rankin; Jennifer M Ogar; La Phengrasamy; Howard J Rosen; Julene K Johnson; Michael W Weiner; Bruce L Miller
Journal:  Ann Neurol       Date:  2004-03       Impact factor: 10.422

10.  Clinicopathological correlates in frontotemporal dementia.

Authors:  John R Hodges; R Rhys Davies; John H Xuereb; Barney Casey; Melissa Broe; Thomas H Bak; Jillian J Kril; Glenda M Halliday
Journal:  Ann Neurol       Date:  2004-09       Impact factor: 10.422

View more
  23 in total

1.  Amyloid in dementia associated with familial FTLD: not an innocent bystander.

Authors:  Georges Naasan; Gil D Rabinovici; Pia Ghosh; Jonathan D Elofson; Bruce L Miller; Giovanni Coppola; Anna Karydas; Jamie Fong; David Perry; Suzee E Lee; Jennifer S Yokoyama; William W Seeley; Joel H Kramer; Michael W Weiner; Norbert Schuff; William J Jagust; Lea T Grinberg; Mochtar Pribadi; Zhongan Yang; Renee Sears; Eric Klein; Kevin Wojta; Howard J Rosen
Journal:  Neurocase       Date:  2015-06-04       Impact factor: 0.881

2.  Novel susceptibility loci for Alzheimer's disease.

Authors:  Christiane Reitz
Journal:  Future Neurol       Date:  2015-12

3.  Mixed TDP-43 proteinopathy and tauopathy in frontotemporal lobar degeneration: nine case series.

Authors:  Eun-Joo Kim; Jesse A Brown; Jersey Deng; Ji-Hye L Hwang; Salvatore Spina; Zachary A Miller; Mary G DeMay; Victor Valcour; Anna Karydas; Eliana Marisa Ramos; Giovanni Coppola; Bruce L Miller; Howard J Rosen; William W Seeley; Lea T Grinberg
Journal:  J Neurol       Date:  2018-10-15       Impact factor: 4.849

Review 4.  The neuropathology of traumatic brain injury.

Authors:  Ann C Mckee; Daniel H Daneshvar
Journal:  Handb Clin Neurol       Date:  2015

Review 5.  Tau and MAPT genetics in tauopathies and synucleinopathies.

Authors:  Etienne Leveille; Owen A Ross; Ziv Gan-Or
Journal:  Parkinsonism Relat Disord       Date:  2021-09-14       Impact factor: 4.402

6.  The Tau/A152T mutation, a risk factor for frontotemporal-spectrum disorders, leads to NR2B receptor-mediated excitotoxicity.

Authors:  Jochen Martin Decker; Lars Krüger; Astrid Sydow; Frank Ja Dennissen; Zuzana Siskova; Eckhard Mandelkow; Eva-Maria Mandelkow
Journal:  EMBO Rep       Date:  2016-03-01       Impact factor: 8.807

7.  Temporal variant of frontotemporal dementia in C9orf72 repeat expansion carriers: two case studies.

Authors:  Francesca Caso; Federica Agosta; Giuseppe Magnani; Rosalinda Cardamone; Valentina Borghesani; Zachary Miller; Nilo Riva; Renaud La Joie; Giovanni Coppola; Lea T Grinberg; William W Seeley; Bruce L Miller; Maria Luisa Gorno-Tempini; Massimo Filippi
Journal:  Brain Imaging Behav       Date:  2020-04       Impact factor: 3.978

Review 8.  Frontotemporal dementia: latest evidence and clinical implications.

Authors:  Juan Joseph Young; Mallika Lavakumar; Deena Tampi; Silpa Balachandran; Rajesh R Tampi
Journal:  Ther Adv Psychopharmacol       Date:  2017-11-10

9.  Tau deposition drives neuropathological, inflammatory and behavioral abnormalities independently of neuronal loss in a novel mouse model.

Authors:  Casey Cook; Silvia S Kang; Yari Carlomagno; Wen-Lang Lin; Mei Yue; Aishe Kurti; Mitsuru Shinohara; Karen Jansen-West; Emilie Perkerson; Monica Castanedes-Casey; Linda Rousseau; Virginia Phillips; Guojun Bu; Dennis W Dickson; Leonard Petrucelli; John D Fryer
Journal:  Hum Mol Genet       Date:  2015-08-13       Impact factor: 6.150

10.  A novel Alzheimer disease locus located near the gene encoding tau protein.

Authors:  G Jun; C A Ibrahim-Verbaas; M Vronskaya; J-C Lambert; J Chung; A C Naj; B W Kunkle; L-S Wang; J C Bis; C Bellenguez; D Harold; K L Lunetta; A L Destefano; B Grenier-Boley; R Sims; G W Beecham; A V Smith; V Chouraki; K L Hamilton-Nelson; M A Ikram; N Fievet; N Denning; E R Martin; H Schmidt; Y Kamatani; M L Dunstan; O Valladares; A R Laza; D Zelenika; A Ramirez; T M Foroud; S-H Choi; A Boland; T Becker; W A Kukull; S J van der Lee; F Pasquier; C Cruchaga; D Beekly; A L Fitzpatrick; O Hanon; M Gill; R Barber; V Gudnason; D Campion; S Love; D A Bennett; N Amin; C Berr; Magda Tsolaki; J D Buxbaum; O L Lopez; V Deramecourt; N C Fox; L B Cantwell; L Tárraga; C Dufouil; J Hardy; P K Crane; G Eiriksdottir; D Hannequin; R Clarke; D Evans; T H Mosley; L Letenneur; C Brayne; W Maier; P De Jager; V Emilsson; J-F Dartigues; H Hampel; M I Kamboh; R F A G de Bruijn; C Tzourio; P Pastor; E B Larson; J I Rotter; M C O'Donovan; T J Montine; M A Nalls; S Mead; E M Reiman; P V Jonsson; C Holmes; P H St George-Hyslop; M Boada; P Passmore; J R Wendland; R Schmidt; K Morgan; A R Winslow; J F Powell; M Carasquillo; S G Younkin; J Jakobsdóttir; J S K Kauwe; K C Wilhelmsen; D Rujescu; M M Nöthen; A Hofman; L Jones; J L Haines; B M Psaty; C Van Broeckhoven; P Holmans; L J Launer; R Mayeux; M Lathrop; A M Goate; V Escott-Price; S Seshadri; M A Pericak-Vance; P Amouyel; J Williams; C M van Duijn; G D Schellenberg; L A Farrer
Journal:  Mol Psychiatry       Date:  2015-03-17       Impact factor: 15.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.